Skip to main content
Top
Published in: International Urology and Nephrology 4/2012

01-08-2012 | Nephrology – Original Paper

Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients

Authors: Ata Firouzi, Ali Eshraghi, Farshad Shakerian, Hamid Reza Sanati, Negar Salehi, Ali Zahedmehr, Reza Kiani, Mohsen Madani, Ali Pedarzadeh

Published in: International Urology and Nephrology | Issue 4/2012

Login to get access

Abstract

Background

Contrast-induced nephropathy (CIN) is an adverse consequence of contrast media use that results in significant morbidity and mortality and adds significant costs to diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CIN and various agents have been tested for its prevention. There is currently a general agreement that adequate pre-procedure hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested pentoxifylline (PTX), an antioxidant, anti-inflammatory drug, for CIN prevention in patients undergoing coronary angioplasty.

Materials and methods

In this prospective, randomized, single-blind, single-center clinical trial, 286 consecutive patients were randomly assigned to the control group (n = 146), with routine treatment and no PTX, or the study group (n = 140), with routine treatment and PTX, 400 mg/tid from 24 h before to 24 h after coronary angioplasty. Serum creatinine was measured before and 2 days after the procedure. The primary end point was the occurrence of CIN within 48 h.

Results

The control and PTX groups were comparable in the overall predicted risk of CIN. Also, the type and volume of the contrast agent were not significantly different between the two groups. Following angioplasty, CIN occurred in 20 (13.69%) patients in the control group and in 12 (8.5%) patients in the study group; the difference was not statistically significant (P = 0.17). Additionally, there was no mortality and need for hemodialysis in either group.

Conclusion

In angioplasty patients, the prophylactic oral use of PTX could be recommended for CIN prevention, although no statistically significant protective effect was documented.
Literature
1.
go back to reference McCullough P (2007) Renal complications of contrast media. In: King Spencer B, Alan C (eds) Interventional cardiology, Chapter 23, 1st edn. McGraw-Hill, China McCullough P (2007) Renal complications of contrast media. In: King Spencer B, Alan C (eds) Interventional cardiology, Chapter 23, 1st edn. McGraw-Hill, China
2.
go back to reference Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ (2008) Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 300(9):1038–1046PubMedCrossRef Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ (2008) Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 300(9):1038–1046PubMedCrossRef
3.
go back to reference Roozbeh J, Hamidian Jahromi A, Sharifian M, Pakfetrat M, Afshariani R (2008) Protective effect of pentoxifylline on contrast induced nephropathy. Saudi J Kidney Dis Transpl 19(6):985–986PubMed Roozbeh J, Hamidian Jahromi A, Sharifian M, Pakfetrat M, Afshariani R (2008) Protective effect of pentoxifylline on contrast induced nephropathy. Saudi J Kidney Dis Transpl 19(6):985–986PubMed
4.
go back to reference Ferrario F, Barone MT, Landoni G, Genderini A, Heidemperger M, Trezzi M, Piccaluga E, Danna P, Scorza D (2009) Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy–a randomized controlled study. Nephrol Dial Transplant 24(10):3103–3107PubMedCrossRef Ferrario F, Barone MT, Landoni G, Genderini A, Heidemperger M, Trezzi M, Piccaluga E, Danna P, Scorza D (2009) Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy–a randomized controlled study. Nephrol Dial Transplant 24(10):3103–3107PubMedCrossRef
5.
go back to reference Gomes VO, Poli de Figueredo CE, Caramori P, Lasevitch R, Bodanese LC, Araújo A, Röedel AP, Caramori AP, Brito FS Jr, Bezerra HG, Nery P, Brizolara A (2005) N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 91(6):774–778PubMedCrossRef Gomes VO, Poli de Figueredo CE, Caramori P, Lasevitch R, Bodanese LC, Araújo A, Röedel AP, Caramori AP, Brito FS Jr, Bezerra HG, Nery P, Brizolara A (2005) N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 91(6):774–778PubMedCrossRef
6.
go back to reference Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D, Sennefelder A, Hennico R, Schenk C, Meining A, Schmelz R, Fritsch R, Weiss W, Hamar P, Heemann U, Schmid RM (2006) Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 239(3):793–804PubMedCrossRef Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D, Sennefelder A, Hennico R, Schenk C, Meining A, Schmelz R, Fritsch R, Weiss W, Hamar P, Heemann U, Schmid RM (2006) Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 239(3):793–804PubMedCrossRef
7.
go back to reference Amini M, Salarifar M, Amirbaigloo A, Masoudkabir F, Esfahani F (2009) N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials 10:45PubMedCrossRef Amini M, Salarifar M, Amirbaigloo A, Masoudkabir F, Esfahani F (2009) N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials 10:45PubMedCrossRef
8.
go back to reference Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS (2009) N-acetylcysteine versus ascorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J 157(3):576–583PubMedCrossRef Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS (2009) N-acetylcysteine versus ascorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J 157(3):576–583PubMedCrossRef
9.
go back to reference Ng TM, Shurmur SW, Silver M, Nissen LR, O’Leary EL, Rigmaiden RS, Cieciorka M, Porter LL, Ineck BA, Kline ME, Puumala SE (2006) Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). Int J Cardiol 109(3):322–328PubMedCrossRef Ng TM, Shurmur SW, Silver M, Nissen LR, O’Leary EL, Rigmaiden RS, Cieciorka M, Porter LL, Ineck BA, Kline ME, Puumala SE (2006) Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). Int J Cardiol 109(3):322–328PubMedCrossRef
10.
go back to reference Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Focaccio A, Ricciardelli B (2004) N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 44(4):762–765PubMedCrossRef Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Focaccio A, Ricciardelli B (2004) N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 44(4):762–765PubMedCrossRef
11.
go back to reference Walker PD, Brokering KL, Theobald JC (2003) Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Pharmacotherapy 23(12):1617–1626PubMedCrossRef Walker PD, Brokering KL, Theobald JC (2003) Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Pharmacotherapy 23(12):1617–1626PubMedCrossRef
12.
go back to reference Bagshaw SM, Ghali WA (2005) Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 165(10):1087–1093PubMedCrossRef Bagshaw SM, Ghali WA (2005) Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 165(10):1087–1093PubMedCrossRef
13.
go back to reference Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N (2002) The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 17(11):1936–1941PubMedCrossRef Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N (2002) The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 17(11):1936–1941PubMedCrossRef
14.
go back to reference Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291(19):2328–2334PubMedCrossRef Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291(19):2328–2334PubMedCrossRef
15.
go back to reference Kanbay M, Covic A, Coca SG, Turgut F, Akcay A, Parikh CR (2009) Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. Int Urol Nephrol 41(3):617–627PubMedCrossRef Kanbay M, Covic A, Coca SG, Turgut F, Akcay A, Parikh CR (2009) Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. Int Urol Nephrol 41(3):617–627PubMedCrossRef
16.
go back to reference Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV (2004) Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110(18):2837–2842PubMedCrossRef Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV (2004) Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110(18):2837–2842PubMedCrossRef
17.
go back to reference Boscheri A, Weinbrenner C, Botzek B, Reynen K, Kuhlisch E, Strasser RH (2007) Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol 68(5):279–286PubMed Boscheri A, Weinbrenner C, Botzek B, Reynen K, Kuhlisch E, Strasser RH (2007) Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol 68(5):279–286PubMed
18.
go back to reference Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, Satler LF, Harvey M, Kent KM, Leon MB (1999) Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 83(2):260–3, A5 Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, Satler LF, Harvey M, Kent KM, Leon MB (1999) Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 83(2):260–3, A5
19.
go back to reference Staudinger T, Presterl E, Graninger W, Locker GJ, Knapp S, Laczika K, Klappacher G, Stoiser B, Wagner A, Tesinsky P, Kordova H, Frass M (1996) Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Intensive Care Med 22(9):888–893PubMedCrossRef Staudinger T, Presterl E, Graninger W, Locker GJ, Knapp S, Laczika K, Klappacher G, Stoiser B, Wagner A, Tesinsky P, Kordova H, Frass M (1996) Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Intensive Care Med 22(9):888–893PubMedCrossRef
20.
go back to reference Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44(7):1393–1399PubMed Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44(7):1393–1399PubMed
Metadata
Title
Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients
Authors
Ata Firouzi
Ali Eshraghi
Farshad Shakerian
Hamid Reza Sanati
Negar Salehi
Ali Zahedmehr
Reza Kiani
Mohsen Madani
Ali Pedarzadeh
Publication date
01-08-2012
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-011-0053-4

Other articles of this Issue 4/2012

International Urology and Nephrology 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.